Correction to: British Journal of Cancer (2019) 121, 249–256; https://doi.org/10.1038/s41416-019-0497-3; www.bjcancer.com; published online 26 June 2019
Since the publication of this paper, the authors have reported that an incorrect version of Fig. 1 was presented. The correct version of Fig. 1 is provided below.
Pooled data from three independent experiments showing OCICx 20 regression and regrowth with RT/RTCT (30 Gy over 3 weeks) and concurrent plerixafor for 3 weeks: no treatment controls (black), plerixafor alone (orange), RT alone (blue), RTCT (red), RTCT and concurrent plerixafor (purple). Each experiment included 5–12 mice per treatment arm. Each data point represents the mean tumour volume in up to 20 mice. A smoothed line was obtained for each treatment group using the ‘loess’ function in R.34 Also shown are the mean tumour volume 95% confidence intervals for the RT, RTCT and RTCT + plerixafor arms. Tumour size was monitored after treatment using weekly CT imaging and volume was estimated using orthogonal tumour dimensions, assuming an elliptical shape. Time was measured from the start of treatment. RT: Radiotherapy; RTCT: Radiotherapy and concurrent cisplatin
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lecavalier-Barsoum, M., Chaudary, N., Han, K. et al. Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy. Br J Cancer 121, 626 (2019). https://doi.org/10.1038/s41416-019-0545-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-019-0545-z
This article is cited by
-
Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
Journal of Experimental & Clinical Cancer Research (2023)
